| Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma L Vercellino, R Di Blasi, S Kanoun, B Tessoulin, C Rossi, M D'Aveni-Piney, ... Blood advances 4 (22), 5607-5615, 2020 | 349 | 2020 |
| Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma S Kanoun, C Rossi, A Berriolo-Riedinger, I Dygai-Cochet, A Cochet, ... European journal of nuclear medicine and molecular imaging 41, 1735-1743, 2014 | 182 | 2014 |
| Genetic basis of congenital erythrocytosis: mutation update and online databases C Bento, MJ Percy, B Gardie, TM Maia, R van Wijk, S Perrotta, ... Human mutation 35 (1), 15-26, 2014 | 157 | 2014 |
| Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy R Duléry, S Lamure, M Delord, R Di Blasi, A Chauchet, T Hueso, C Rossi, ... American Journal of Hematology 96 (8), 934-944, 2021 | 144 | 2021 |
| Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies P Gravelle, B Burroni, S Péricart, C Rossi, C Bezombes, M Tosolini, ... Oncotarget 8 (27), 44960, 2017 | 128 | 2017 |
| Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F] FDG PET to predict survival in Hodgkin lymphoma S Kanoun, I Tal, A Berriolo-Riedinger, C Rossi, JM Riedinger, ... PloS one 10 (10), e0140830, 2015 | 122 | 2015 |
| Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial S Le Gouill, F Morschhauser, D Chiron, K Bouabdallah, G Cartron, ... Blood, The Journal of the American Society of Hematology 137 (7), 877-887, 2021 | 121 | 2021 |
| Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: a series from lysa centers C Rossi, J Gilhodes, M Maerevoet, C Herbaux, F Morschhauser, P Brice, ... American Journal of Hematology 93 (8), 1042-1049, 2018 | 104 | 2018 |
| Leucocytosis and thrombosis at diagnosis are associated with poor survival in polycythaemia vera: a population‐based study of 327 patients G Bonicelli, K Abdulkarim, M Mounier, P Johansson, C Rossi, V Jooste, ... British journal of haematology 160 (2), 251-254, 2013 | 100 | 2013 |
| Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in Hodgkin lymphoma patients C Rossi, S Kanoun, A Berriolo-Riedinger, I Dygai-Cochet, O Humbert, ... Journal of Nuclear Medicine 55 (4), 569-573, 2014 | 92 | 2014 |
| Accurate diagnosis of lymphoma on whole-slide histopathology images using deep learning C Syrykh, A Abreu, N Amara, A Siegfried, V Maisongrosse, FX Frenois, ... NPJ digital medicine 3 (1), 63, 2020 | 88 | 2020 |
| Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma E Lemieux, C Hulin, D Caillot, S Tardy, V Dorvaux, J Michel, T Gastinne, ... Biology of Blood and Marrow Transplantation 19 (3), 445-449, 2013 | 83 | 2013 |
| Determinants of outcome in Covid-19 hospitalized patients with lymphoma: a retrospective multicentric cohort study S Lamure, R Duléry, R Di Blasi, A Chauchet, C Laureana, B Deau-Fischer, ... EClinicalMedicine 27, 2020 | 71 | 2020 |
| Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphoma C Rossi, P Gravelle, E Decaup, J Bordenave, M Poupot, M Tosolini, ... Oncoimmunology 8 (3), 1554175, 2019 | 69 | 2019 |
| Molecular study of congenital erythrocytosis in 70 unrelated patients revealed a potential causal mutation in less than half of the cases (Where is/are the missing gene (s)?) C Bento, H Almeida, TM Maia, L Relvas, AC Oliveira, C Rossi, F Girodon, ... European journal of haematology 91 (4), 361-368, 2013 | 68 | 2013 |
| Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients J Rohmer, A Couteau‐Chardon, J Trichereau, K Panel, C Gesquiere, ... American Journal of Hematology 95 (11), 1314-1323, 2020 | 55 | 2020 |
| Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified E Bourbon, D Maucort-Boulch, J Fontaine, C Mauduit, P Sesques, V Safar, ... Blood advances 5 (16), 3227-3239, 2021 | 50 | 2021 |
| Distinct Hodgkin lymphoma subtypes defined by noninvasive genomic profiling SK Alig, M Shahrokh Esfahani, A Garofalo, MY Li, C Rossi, T Flerlage, ... Nature 625 (7996), 778-787, 2024 | 49 | 2024 |
| Clinical and economic impact of pharmacist interventions in an ambulatory hematology–oncology department J de Grégori, P Pistre, M Boutet, L Porcher, M Devaux, C Pernot, ... Journal of Oncology Pharmacy Practice 26 (5), 1172-1179, 2020 | 49 | 2020 |
| CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell–targeted therapies M Le Cann, F Bouhour, K Viala, L Simon, C Tard, C Rossi, G Morel, ... Blood, The Journal of the American Society of Hematology 136 (21), 2428-2436, 2020 | 48 | 2020 |
LAURENTlaboratoire de PathologieAdresse e-mail validée de chu-toulouse.fr
